Glucose Health, Inc.
GLUC evidence brief
What we can confirm
- BioSniper Score:
- 6.0 / 10
- Market Cap:
- $8.0M
- Lead Asset:
- glucose health (Approved)
What it means
What to watch
Prepared research question
What matters most for GLUC—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · GLUC
Glucose Health, Inc. (OTC: GLUC) is a consumer health company focused on soluble-fiber nutritional products for metabolic wellness and blood sugar management, with its GlucoDown brand gaining retail traction.
Key risk: Zero cash and negative equity
BioSniper Score
Based on 3 of 6 signals
Limited data coverage
Market Cap
$8.0M
Cash Runway
—
Lead Asset
glucose health (Approved)
Next Catalyst
—
Financial data as of Sep 30, 2017.
Tracking 2 pipeline candidates for Glucose Health, Inc..
Glucose Health, Inc. (OTC: GLUC) is a consumer health company focused on soluble-fiber nutritional products for metabolic wellness and blood sugar management, with its GlucoDown brand gaining retail traction.
- Glucose Health markets GlucoDown, a nutritional beverage enriched with soluble fiber that clinical data indicates can reduce the body's metabolism of dietary sugars [news · 2026-06-18].
- The company reported a debt-free balance sheet as of January 2026 after settling a $225,000 note [news · 2026-01-14].
- As of September 30, 2017, the company reported cash & equivalents of $0.0M, net income of $0.0M, and negative shareholders' equity of -$0.4M [sec].
- In August 2026, Glucose Health appointed John Duffy, a 20-year veteran of Coca-Cola Enterprises and The Coca-Cola Company, as CEO [news · 2026-08-28].
- The company's pipeline candidate is an approved dietary supplement for pre-diabetes and Type-2 diabetes, formulated from nine natural ingredients [pipeline].
What works
- The company achieved a debt-free balance sheet in January 2026, eliminating a $225,000 loan liability [news · 2026-01-14].
- GlucoDown sales are surging in national pharmacy chains, raising the growth outlook for 2026 [news · 2026-06-18].
- The appointment of a seasoned consumer packaged goods executive as CEO may strengthen brand leadership and distribution [news · 2026-08-28].
What to weigh
- The company's latest reported financials (as of September 30, 2017) show zero cash, zero net income, and negative shareholders' equity of -$0.4M [sec].
- Glucose Health operates in a highly competitive market with large pharmaceutical companies (e.g., Novo Nordisk, Eli Lilly, Sanofi) conducting advanced clinical trials for diabetes interventions [competitor_trial].
- The company's product is a dietary supplement, which may face lower barriers to entry but also limited clinical differentiation compared to prescription drugs [pipeline].
From the filings
Quoted directly from source documents.
GlucoDown's soluble fiber reduces metabolism of dietary sugars
“clinical data indicates, can reduce your body's metabolism of dietary sugars”
News · June 18, 2026
Debt-free balance sheet after note settlement
“successfully negotiated a Note Settlement Agreement with Board member, Edmund J. Burke. This note, representing a loan to Glucose Health, in the principal amount of $225,000”
News · January 14, 2026
Appointment of John Duffy as CEO
“Appoints Consumer Products Industry Veteran John Duffy as Chief Executive Officer to Accelerate Growth, Elevate Brand Leadership, and Maximize Long-Term Shareholder”
News · August 28, 2026
Pipeline product is an approved dietary supplement for pre-diabetes and Type-2 diabetes
“dietary supplement formulated from nine natural ingredients shown in certain clinical research... to have a beneficial impact upon blood glucose, insulin, triglyceride and cholesterol levels”
Risks & what to watch (3)›
Key risks
- Zero cash and negative equity — As of 2017-09-30, cash $0.0M, net income $0.0M, shareholders' equity -$0.4M [sec].
- Intense competition from pharma giants — Multiple large companies (Novo Nordisk, Eli Lilly, Sanofi) have advanced diabetes trials [competitor_trial].
- Supplement vs. drug differentiation — Product is a dietary supplement, not a prescription drug, limiting clinical differentiation [pipeline].
What to watch
- Monitor revenue growth and cash position updates, as latest financials are from 2017 [sec].
- Track GlucoDown sales momentum in national pharmacy chains [news · 2026-06-18].
- Observe impact of new CEO John Duffy on brand expansion and distribution [news · 2026-08-28].
- Watch for any new clinical data or regulatory developments for the pipeline supplement [pipeline].
Sources: Competitor trials · News · Pipeline · Generated October 2, 2026 · How we verify sources →
Run Glucose Health, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Glucose Health, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 3 of 6 signals · derived from public data
Cash runway data unavailable
Net income $19K
Lead: Approved
2 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Pipeline
Financials
Governance
Frequently asked questions
What is the AI investment thesis for Glucose Health, Inc.?
Glucose Health, Inc. (OTC: GLUC) is a consumer health company focused on soluble-fiber nutritional products for metabolic wellness and blood sugar management, with its GlucoDown brand gaining retail traction.
What is Glucose Health, Inc.'s lead drug candidate?
Glucose Health, Inc.'s most advanced tracked candidate is glucose health (Approved) for pre-diabetes and Type-2 diabetes.
Who is the CEO of Glucose Health, Inc.?
Mr. John Duffy is the chief executive officer of Glucose Health, Inc. (GLUC).
Where is Glucose Health, Inc. headquartered?
Glucose Health, Inc. (GLUC) is headquartered in Bentonville, AR, United States.
What therapeutic areas does Glucose Health, Inc. focus on?
Glucose Health, Inc. develops therapies across Metabolic.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.